VALUE Study (Correction)
This article was originally published in The Pink Sheet Daily
Executive Summary
The VALUE study found that fewer patients treated with Pfizer's Norvasc (amlodipine) had heart attacks (fatal and non-fatal) than patients on Novartis' Diovan (valsartan)